Post-Approval Changes Lead FDA's FY18 Drug Manufacturing Regulatory Agenda
Executive Summary
FDA's US regulatory agenda for pharmaceutical manufacturing in FY 2018 includes post-approval changes, outsourcing GMPs, irradiation and more.
You may also be interested in...
Generic Labeling Rule Dies In Latest Reg Agenda, But Electronic Labeling Is Reborn
US FDA also indicated plans to update definition of biologic product and propose a one-page Patient Medication Information in the latest Unified Agenda.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.
US FDA, USP Raise Questions About Valisure’s Assertions Of Benzoyl Peroxide’s Benzene Risks
The US drug regulatory authority and standard-setting organization are evaluating the drug-screening venture’s findings regarding stability and potential carcinogenic risks associated with the widely used acne treatment, which includes Rx formulations.